Presentation highlights Blacksmith’s novel chemistry platform for targeting metalloenzymes and FG-2101, a first-in-class non-hydroxamate LpxC inhibitor SAN DIEGO, Aug. 1, 2025 /PRNewswire/ — Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing […]
